On this episode of Stock Movers:
- French luxury group LVMH is on track for a seventh straight session of losses, the longest streak since March, after US President Donald Trump signaled he could impose a 200% tariff on French wines and champagne. 
- Ferretti’s second-largest investor is preparing to propose a shareholder vote to oust directors with connections to the yacht maker’s top owner, China’s Weichai Group, according to people familiar with the matter. 
- GSK agreed to buy Rapt Therapeutics, a US-based biotech developing treatments for patients with inflammatory and immunologic diseases, in a deal valued at $2.2 billion.

On this episode of Stock Movers: - French luxury group LVMH is on track for a seventh straight session of losses, the longest streak since March, after US President Donald Trump signaled he could impose a 200% tariff on French wines and champagne. - Ferretti&rsquo;s second-largest investor is preparing to propose a shareholder vote to oust directors with connections to the yacht maker&rsquo;s top owner, China&rsquo;s Weichai Group, according to people familiar with the matter. - GSK agreed to buy Rapt Therapeutics, a US-based biotech developing treatments for patients with inflammatory and immunologic diseases, in a deal valued at $2.2 billion.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for news on today's biggest winners and losers in the stock market.

Stock Movers

LVMH Losses, Ferritti Plot, GSK Rapt

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/eac133f4-a0fa-455d-958e-b3d800a76294/transcript